Last reviewed · How we verify
GZ17-6.02
At a glance
| Generic name | GZ17-6.02 |
|---|---|
| Sponsor | Genzada Pharmaceuticals USA, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy (PHASE1)
- Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |